A Phase 3 interventional study of Dulaglutide and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is the only one that started in 2014, is one of 22 in phase 3, and was the 29th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 95th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2014, is one of 85 in phase 3, and was the 110th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Are females of who must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
Drug: Dulaglutide · Drug: Insulin Glargine · Drug: Metformin
Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
Drug: Placebo · Drug: Insulin Glargine · Drug: Metformin
Administered SQ
Also known as: LY2189265
Administered SQ
Administered SQ
Administered orally
Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least-squares (LS) mean and standard error (SE) changes from baseline in HbA1c at 28 weeks were measured using mixed model regression and restricted maximum likelihood (REML) with treatment, pooled country, visit, and treatment-by -visit interaction as fixed effects, baseline as covariate, and participant as a random effect.
Time frame: Baseline, 28 Weeks
Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)
FSG is a test to determine glucose levels after an overnight fast. LS means FSG change from baseline to primary endpoint at week 28 was calculated using a mixed effects model for repeated measures (MMRM) analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline FSG as covariate.
Time frame: Baseline, 28 Weeks
Change From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)
The LS means of the 7-point SMPG change from baseline to primary endpoint at week 28 was measured using a MMRM analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline SMPG as covariate.
Time frame: Baseline, 28 Weeks
Change From Baseline to 28 Weeks in Body Weight
LS means of the body weight change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline body weight as covariate, via a MMRM analysis.
Time frame: Baseline, 28 Weeks
Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose
Least Square (LS) Means of the insulin dose change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline insulin dose as covariate, via a MMRM analysis.
Time frame: Baseline, 28 Weeks
Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events
Cardiovascular (CV) adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the sponsor. Deaths occurring during the study treatment period and nonfatal CV AEs were to be adjudicated. Nonfatal CV events that were to be adjudicated were myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (CVA/stroke), and transient ischemic attack (TIA).
Time frame: Baseline through 28 Weeks
Percentage of Participants With Self-Reported Events of Hypoglycemia
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The percentage of participants with self-reported hypoglycemic events is presented.
Time frame: Baseline through 28 Weeks
Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia
Time frame: Baseline through 28 Weeks
Number of Participants With Adjudicated Acute Pancreatitis Events
The number of cases of acute pancreatitis confirmed by adjudication. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline through 28 Weeks
Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)
Time frame: Baseline through 28 Weeks
Number of Participants With Dulaglutide Anti-Drug Antibodies
Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 12 and 28. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
Time frame: Baseline, Week 12 and Week 28
Percentage of Participants Achieving HbA1c Targets of <7.0% or ≤6.5%
Percentage of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.
Time frame: 28 Weeks
Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)
Percentage of participants who achieved a target HbA1c target of \<7%, without weight gain and without documented symptomatic hypoglycemia at 28 weeks were analyzed using regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.
Time frame: 28 Weeks
Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)
Percentage of participants achieving target HbA1c of \<7.0% at 28 weeks without documented symptomatic hypoglycemia are presented. Documented symptomatic hypoglycemia is defined as any time a participant experienced symptoms and or signs associated with hypoglycemia and had a plasma glucose of \<=70 mg/dL.
Time frame: 28 Weeks
Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)
Time frame: 28 Weeks
Rate of Hypoglycemic Events up to 28 Weeks
The rate of total hypoglycemic events any type per 30 days is presented. The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.
Time frame: Baseline through 28 Weeks
| Milestone | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Started | 150 | 150 |
| Received at least 1 dose of study drug. | 150 | 150 |
| Completed | 138 | 134 |
| Not completed | 12 | 16 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Withdrawal by subject | 3 | 7 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Reason not given | 0 | 1 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least-squares (LS) mean and standard error (SE) changes from baseline in HbA1c at 28 weeks were measured using mixed model regression and restricted maximum likelihood (REML) with treatment, pooled country, visit, and treatment-by -visit interaction as fixed effects, baseline as covariate, and participant as a random effect.
| percentage of change | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c) | -1.44 ± 0.09 | -0.67 ± 0.09 |
FSG is a test to determine glucose levels after an overnight fast. LS means FSG change from baseline to primary endpoint at week 28 was calculated using a mixed effects model for repeated measures (MMRM) analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline FSG as covariate.
| milligram per deciliter (mg/dL) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG) | -44.63 ± 4.16 | -27.90 ± 4.08 |
The LS means of the 7-point SMPG change from baseline to primary endpoint at week 28 was measured using a MMRM analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline SMPG as covariate.
| mg/dL | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Pre-Morning Meal (n=133,129) | -44.03 ± 2.71 | -35.97 ± 2.64 |
| Morning Meal 2-Hour Postprandial (n=123,119) | -64.16 ± 4.31 | -46.97 ± 4.27 |
| Pre-Midday Meal (n=133,127) | -40.89 ± 3.72 | -25.34 ± 3.62 |
| Midday Meal 2-Hour Post Prandial (n=123,117) | -51.13 ± 4.40 | -32.98 ± 4.33 |
| Pre-Evening Meal (n=133,129) | -43.68 ± 4.21 | -28.71 ± 4.07 |
| Evening Meal 2-Hour Postprandial (n=126,122) | -48.63 ± 5.22 | -27.35 ± 5.16 |
| 3:00 AM (Morning) (n=124,117) | -39.77 ± 4.27 | -20.30 ± 4.23 |
LS means of the body weight change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline body weight as covariate, via a MMRM analysis.
| kilogram(kg) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Change From Baseline to 28 Weeks in Body Weight | -1.91 ± 0.30 | 0.50 ± 0.30 |
Least Square (LS) Means of the insulin dose change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline insulin dose as covariate, via a MMRM analysis.
| units (u) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose | 12.75 ± 2.27 | 25.94 ± 2.30 |
Cardiovascular (CV) adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the sponsor. Deaths occurring during the study treatment period and nonfatal CV AEs were to be adjudicated. Nonfatal CV events that were to be adjudicated were myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (CVA/stroke), and transient ischemic attack (TIA).
| participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events | 3 | 1 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The percentage of participants with self-reported hypoglycemic events is presented.
| percentage of participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Symptomatic | 35.3 | 30.0 |
| Asymptomatic | 42.7 | 39.3 |
| Severe | 0.7 | 0.0 |
| Nocturnal | 28.0 | 28.7 |
| Probable Symptomatic | 2.7 | 2.0 |
| percentage of participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia | 0 | 0 |
The number of cases of acute pancreatitis confirmed by adjudication. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Number of Participants With Adjudicated Acute Pancreatitis Events | 0 | 0 |
| participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia) | 1 | 0 |
Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 12 and 28. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
| participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Number of Participants With Dulaglutide Anti-Drug Antibodies | 0 | 2 |
Percentage of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.
| percentage of participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| HbA1c <= 6.5 | 50.7 | 16.7 |
| HbA1c < 7.0 | 69.3 | 35.3 |
Percentage of participants who achieved a target HbA1c target of \<7%, without weight gain and without documented symptomatic hypoglycemia at 28 weeks were analyzed using regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.
| percentage of participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28) | 40.7 | 16.7 |
Percentage of participants achieving target HbA1c of \<7.0% at 28 weeks without documented symptomatic hypoglycemia are presented. Documented symptomatic hypoglycemia is defined as any time a participant experienced symptoms and or signs associated with hypoglycemia and had a plasma glucose of \<=70 mg/dL.
| percentage of participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28) | 52.0 | 28.0 |
| percentage of participants | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg) | 52.7 | 20.0 |
The rate of total hypoglycemic events any type per 30 days is presented. The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.
| rate of hypoglycemic events per 30 days | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| Rate of Hypoglycemic Events up to 28 Weeks | 0.63 ± 1.24 | 0.70 ± 1.32 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dulaglutide + Insulin Glargine | — | 9/150 (6%) | 51/150 (34%) |
| Placebo + Insulin Glargine | — | 7/150 (4.7%) | 29/150 (19.3%) |
| Event | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| BradycardiaCardiac disorders | 2/150 | 0/150 |
| Transient ischaemic attackNervous system disorders | 2/150 | 0/150 |
| Angina unstableCardiac disorders | 1/150 | 1/150 |
| Atrial fibrillationCardiac disorders | 1/150 | 0/150 |
| Coronary artery diseaseCardiac disorders | 1/150 | 0/150 |
| Myocardial infarctionCardiac disorders | 1/150 | 0/150 |
| Non-cardiac chest painGeneral disorders | 0/150 | 1/150 |
| Granulomatous liver diseaseHepatobiliary disorders | 1/150 | 0/150 |
| GastroenteritisInfections and infestations | 1/150 | 0/150 |
| Viral infectionInfections and infestations | 0/150 | 1/150 |
| Event | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine |
|---|---|---|
| NauseaGastrointestinal disorders | 18/150 | 2/150 |
| DiarrhoeaGastrointestinal disorders | 17/150 | 6/150 |
| NasopharyngitisInfections and infestations | 6/150 | 14/150 |
| Upper respiratory tract infectionInfections and infestations | 11/150 | 10/150 |
| Decreased appetiteMetabolism and nutrition disorders | 10/150 | 0/150 |
| DyspepsiaGastrointestinal disorders | 9/150 | 0/150 |
| VomitingGastrointestinal disorders | 9/150 | 0/150 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| Mean | 60.2 ± 9.47 | 60.6 ± 10.07 | 60.4 ± 9.76 |
| Sex: Female, Male(Participants) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| Female | 65 | 62 | 127 |
| Male | 85 | 88 | 173 |
| Ethnicity (NIH/OMB)(Participants) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 25 | 51 |
| Not Hispanic or Latino | 104 | 104 | 208 |
| Unknown or Not Reported | 20 | 21 | 41 |
| Race (NIH/OMB)(Participants) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 5 | 6 | 11 |
| White | 143 | 138 | 281 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| Czech Republic | 25 | 27 | 52 |
| Puerto Rico | 12 | 16 | 28 |
| Hungary | 37 | 35 | 72 |
| United States | 32 | 29 | 61 |
| Italy | 13 | 15 | 28 |
| United Kingdom | 2 | 2 | 4 |
| Spain | 29 | 26 | 55 |
| Mean Insulin Glargine Dose(Units (U)) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| Mean | 40.71 ± 23.12 | 36.59 ± 21.46 | 38.65 ± 22.37 |
| Metformin Use at Baseline(participants) | Dulaglutide + Insulin Glargine | Placebo + Insulin Glargine | Total |
|---|---|---|---|
| Treated with Metformin | 134 | 131 | 265 |
| Not Treated with Metformin | 16 | 19 | 35 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of May 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide